Was ist gesichert in der Therapie der Mukoviszidose?-Reference-Cited by-同舟云学术

Was ist gesichert in der Therapie der Mukoviszidose?

Published:2020-11-17 Issue:12 Volume:61 Page:1212-1229
ISSN:0020-9554
Container-title:Der Internist
language:de
Short-container-title:Internist

Author:

Ringshausen F. C.,Hellmuth T.,Dittrich A.‑M.

Publisher

Springer Science and Business Media LLC

Subject

Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00108-020-00896-9.pdf

Reference84 articles.

1. Adjemian J, Olivier KN, Prevots DR (2018) Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010–2014. Ann Am Thorac Soc 15:817–826

2. Ahmed MI, Mukherjee S (2018) Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011581.pub3

3. Amin R, Jahnke N, Waters V (2020) Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009249.pub5

4. Andrejak C, Nielsen R, Thomsen VO et al (2013) Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 68:256–262

5. Balazs A, Mall MA (2019) Mucus obstruction and inflammation in early cystic fibrosis lung disease: emerging role of the IL‑1 signaling pathway. Pediatr Pulmonol 54(Suppl 3):S5–S12

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosing Cystic Fibrosis in the 21st Century—A Complex and Challenging Task;Diagnostics;2024-04-03

2. Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians;Respiration;2022

3. Lumacaftor and Matrine: Possible Therapeutic Combination to Counteract the Inflammatory Process in Cystic Fibrosis;Biomolecules;2021-03-13

4. Risikoabschätzung bei Patienten mit chronischen Atemwegs- und Lungenerkrankungen im Rahmen der SARS-CoV-2-Pandemie;Pneumologie;2020-11-26